134,389 research outputs found
Dedication Program of the Florence B. Price School, November 24, 1964, Including Performances of Works by Florence Price
No full textPiano Concerto No. 1; It's Snowing; Violin Concerto No. 2, or Concertos, Piano, Orchestra, D MinorDedication program of the Florence B. Price School, November 24, 1964.Lists Chicago Board of Education members, teachers, and staff of the school.Dedication Program
of the
Florence B. Price School
Tuesday, November 24, 1964
1:00 P.MCHICAGO BOARD OF EDUCATION
Mr. Frank W. Whiston. President
Mr. Thomas J. Murray. V ice-President
Mr. Cyrus H. Adams III
Mr. Warren H. Bacon
Mr. James W. Clement
Mr. Bernard S. Friedman Mrs. Wendell E. Green Mrs. Louis A. Malis Mr. Raymond W. Pasnick Mr. Edward S. Scheffler Mrs. W. Lydon Wild
Dr. Benjamin C. Willis General Superintendent of Schools
Dr. James H. Smith Deputy Superintendent of Schools
Dr. Milton J. Cohler
Associate Superintendent in charge of administration Mrs. Evelyn F. Carlson
Associate Superintendent in charge of curriculum development Dr. Eileen C. Slack
Associate Superintendent in charge of higher education Dr. James H. Smith
Associate Superintendent in charge of instruction (south section) Dr. Edwin C. Lederer
Associate Superintendent in charge of operation services
Dr. John F. Erzinger Superintendent of District ThirteenProgram
POSTING OF COLORS.........................................................Color Guard
PLEDGE OF ALLEGIANCE
NATIONAL ANTHEM .................................................................Audience
Mr. Melvin J. Widman, Music Supervisor
INVOCATION Reverend Augustus Bennett
Retired Pastor, Grace Presbyterian, Church
WELCOME Pupil, Grade 6
SELECTION: PIANO CONCERTO NO. 1 (Florence B. Price)
1st Piano—Eugenia Wright Anderson 2nd Piano—Judith Hulse Hill
ACKNOWLEDGEMENT OF GUESTS
INTRODUCTION OF GUEST SPEAKER Dr. John F. Erzinger
DEDICATORY ADDRESS ........................................Dr. Eileen C. Stack
Associate Superintendent
SONG................................................................................Pupils of Grade 2
Miss Joannilou Huff Conducting “It’s Snowing” ( Florence B. Price)
FLORENCE B. PRICE Mrs. Mary A. Saxton
Principal
SELECTION: VIOLIN CONCERTO NO. 2 (Florence B. Price)
Minnie Cedargreen Jernberg Evelyn Nelson Russell at the Piano
PRESENTATION OF MEMORIAL Bernice Nelson Skooglund
SONG Price Chorus
“Bless Our School'’FLORENCE B. PRICE ELEMENTARY SCHOOL
Mary A. Saxton. Principal
Paul R. Barnett Adele Beaton Norma C. Brown Ann S. Cabaniss Agnes L. Carter Hannah H. Christian Charon Deruisa Addie N. Dunlap Vivian E. Gilliam Alice R. Harris Toni Y. Hornsberger Raymel Horton Joannilou Huff Elouise P. Johnson Leroy L. Johnson Hettie F. Jones Laura A. Keeter Bernice E. Kerr Frances W. Larrieu
Lillian Y. McCoy Helen B. Murray Violet Nathan Mary V. Pitts Patricia C. Potter Leona J. Qualls Lula L. Rucker Edith R. Scheer Naomiruth M. Scott Iva Nell Slack Henry A. Spaulding Dixie W. Taylor Marjorie D. Taylor Nancy B. Taylor Edyth M. Tillman Laurita E. Towles Miriam E. Turner Barbara J. Walker Katherine A. Watkins
Lovelace Lee
Clerks
Christine J. Downz
Thelma Perkins
Engineering Staff
Franklin Trauscht, Engineer Charles Bradley
Richard Joslyn, Fireman George Morgan
Perry Jefferson Rosa Thornton
Luncheon
Augustine Dixon. Cook-Manager Roberta Broome Orvetta Johnson
Melvin J. Widman. Music Supervisor Joseph Young, Art Supervisor Roxie Monroe, Attendance Officer Bertha Johnson, Nurse Rosa Brown, Psychologist Nevis Phillips. Speech Therapis
R&D and Price Elasticity of Demand
No full textThis note explores the relationship between the price elasticity of demand and the R&D intensity of the product. We introduce the concept of R&D intensity into a standard Dixit-Stiglitz/Krugman-type setting. R&D activity is treated as a fixed cost of production. Within this framework, sectors with a higher R&D intensity show a lower price elasticity of demand. This proposition is confirmed by an empirical investigation of export demand for manufactured goods from major industrialised countries. Consequently, real exchange rate changes have an impact on the commodity structure of exports.R&D intensity; Price elasticity; Exports
Violin Concerto No. 2, by Florence B. Price, Violin II Part, with Handwritten Notation
No full textViolin Concerto No. 2Music manuscript for Violin Concerto No. 2 written by Florence B. Price, May 1952.VIOLIN II.
VIOLIN CONCERTO
No. 2
Florence B. Price
ASCAP
Tempo moderato d -132
May, 1952
No. 1 THE KAYSER MUSIC BINDING CO. 12 staves 64 E. Jackosn Bl'd Chicago, Ill.
mf
mp
cresl
mf
66
62
58
poco rrl
47
41
35
poco meno
27
19
10
4
3
2
mp
cresl
mf
5
f
11
20
mp
3
rit
mf
Pizz
28
rit
poco piu mosso
fit pizz
mp
a tempo
3
36
mf
arcg
mf
p
a tempo
2
mp
mp
42
48
60
54
59
p
mp
mf
pizz
p
pizz
6
Adoration, by Florence B. Price, an Organ Score with Organ Stops Listed
No full textAdorationScore for Adoration by Florence B. Price.ADORATION
3 1/2 minutes
Sw. Horn D# Prepare b 13 3545 430
Gt. Dulc. D
Ped. Ged. Ped. 31, Chorus
FLORENCE B. PRICE
Andante = 84
Sw.
Gt.
p
rit.
a tempo
2nd time to Coda
poco rit.
a tempo
Sw.
Gt.
mf
mp
Gt.A little slower
Sw.Strings 8', 4', 16'
B p
f
poco riten.
rnf a tempo
D.C.
mp
Sw.
Horn
D#
CODA
mf
f
rit. e dim
European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending
No full textEU countries closely regulate pharmaceutical prices whereas the U.S. does not. This paper shows how price constraints affect the profitability, stock returns, and R&D spending of EU and U.S. firms. Compared to EU firms, U.S. firms are more profitable, earn higher stock returns, and spend more on research and development (R&D). Some differences have increased over time. In 1986, EU pharmaceutical R&D exceeded U.S. R&D by about 24 percent, but by 2004, EU R&D trailed U.S. R&D by about 15 percent. During these 19 years, U.S. R&D spending grew at a real annual compound rate of 8.8 percent, while EU R&D spending grew at a real 5.4 percent rate. Results show that EU consumers enjoyed much lower pharmaceutical price inflation, however, at a cost of 46 fewer new medicines introduced by EU firms and 1680 fewer EU research jobs.
Pharmaceutical Stock Price Reactions to Price Constraint Threats and Firm-Level R&D Spending
No full textPolitical pressure in the United States is again building to constrain pharmaceutical prices either directly or through legalized reimportation of lower-priced pharmaceuticals from foreign countries. This study uses the Clinton Administration's Health Security Act (HSA) of 1993 as a natural experiment to show how threats of price constraints affect firm-level R&D spending. We link events surrounding the HSA to pharmaceutical company stock price changes and then examine the cross-sectional relation between the stock price changes and subsequent unexpected R&D spending changes. Results show that the HSA had significant negative effects on firm stock prices and R&D spending. Conservatively, the HSA reduced R&D spending by $1.6 billion, even though it never became law. If the HSA had passed, and had many small firms not raised capital just prior to the HSA, the R&D effects could have been much larger.
Price hedonics: a critical review
No full textThis paper was presented at the conference "Economic Statistics: New Needs for the Twenty-First Century," cosponsored by the Federal Reserve Bank of New York, the Conference on Research in Income and Wealth, and the National Association for Business Economics, July 11, 2002. The main objective of this paper is to make a start in the evaluation of price hedonics. The author describes the hedonic model and reviews its main uses, because the credibility of price hedonics depends in part on the current state of academic research. This is a brief overview. The author then turns to some of the standard criticisms of price hedonics and moves into the uncharted waters of the political economy of price measurement.Statistics ; Prices ; Consumer price indexes
Description of author Lisa Price\u27s hiking trip through the Hundred Mile Wilderne
No full textDescription of author Lisa Price\u27s hiking trip through the Hundred Mile Wilderness, the final section of the Appalachian Trail in Maine. Price, who has hiked the Appalachian Trail for four years, one section at a time, meets up with fellow hikers Noel and Caroline at Shaw\u27s Boarding House in Monson, and the three reach the summit of Mount Katahdin together
[Gas Mileage Ration Folder for F. D. Wyatt]
No full textMileage ration folder belonging to F. D. Wyatt, valid from June 13, 1945 until September 13, 1945. This card is folded down the center creating a place to put coupons for gas rations inside; the note on the front says: "Any Person Finding Lost Coupons Should Mail or Return Them at Once to the Nearest War Price and Rationing Board.
The Cost of US Pharmaceutical Price Reductions: A Financial Simulation Model of R&D Decisions
No full textPrevious empirical studies that have examined the links between pharmaceutical price controls, profits, cash flows, and investment in research and development (R&D) have been largely based on retrospective statistical analyses of firm- and/or industry-level data. These studies, which have contributed numerous insights and findings to the literature, relied upon ad hoc reduced-form model specifications. In the current paper we take a very different approach: a prospective micro-simulation approach. Using Monte Carlo techniques we model how future price controls in the U.S. will impact early-stage product development decisions in the pharmaceutical industry. This is done within the context of a net present value (NPV) framework that appropriately reflects the uncertainty associated with R&D project technical success, development costs, and future revenues. Using partial-information estimators calibrated with the most contemporary clinical and economic data available, we demonstrate how pharmaceutical price controls will significantly diminish the incentives to undertake early-stage R&D investment. For example, we estimate that cutting prices by 40 to 50 percent in the U.S. will lead to between 30 to 60 percent fewer R&D projects being undertaken (in early-stage development). Given the recent legislative efforts to control prescription drug prices in the U.S., and the likelihood that price controls will prevail as a result, it is important to better understand the firm response to such a regulatory change.
- …
